US stocks anomaly | Lee received a $1.3 billion premium in a 130% acquisition of Verve Therapeutics (VERV.US), which surged over 74%

Wisdom Finance app learned that on Tuesday, Verve Therapeutics (VERV.US) surged over 74%, reaching $10.99. According to media reports, the world's largest pharmaceutical giant, Gilead Sciences, is preparing to acquire the gene editing startup Verve Therapeutics for up to $1.3 billion, with $1 billion as an upfront payment and an additional $300 million to be paid based on specific clinical milestones reached by Verve. For Verve, this is undoubtedly a very attractive deal.